Opioid Withdrawal

Welcome back to AudioBoards and another episode in our Intern Series — a crash course designed to help medical students, interns, and early trainees master the high-yield conditions they’ll encounter on the wards. Opioid withdrawal is an especially important topic because it’s incredibly common in emergency medicine, internal medicine, psychiatry, and inpatient care. Recognizing withdrawal early, understanding the physiology behind it, and knowing how to manage it safely can dramatically improve patient outcomes, reduce relapse risk, and, in many cases, save lives.

Transcript

Opioid withdrawal occurs when someone physically dependent on opioids reduces or stops use. While withdrawal is usually not fatal, it causes profound physical and psychological distress that often drives people back to opioid use. Importantly, withdrawal management is not a standalone treatment for opioid use disorder, or OUD — it should be part of a broader recovery plan.

To understand opioid withdrawal, it helps to think of it as a “systemic rebound.” Opioids act like a comfort dial in the brain and body. They reduce pain, anxiety, heart rate, gut activity, and stress by activating μ-opioid receptors. With chronic opioid use, the body adapts by reducing its natural calming systems while increasing stress chemicals like norepinephrine to maintain balance. When opioids suddenly stop, the calming effect disappears, but the stress system remains overactive. The result is a rebound hyper-arousal state that produces the classic withdrawal syndrome: diffuse pain, anxiety, agitation, sweating, goosebumps, runny nose, tearing, nausea, vomiting, diarrhea, muscle cramps, tachycardia, hypertension, and intense cravings. Many patients describe it as feeling like the worst flu imaginable combined with a panic attack.

Although opioid withdrawal feels “death-like,” it is rarely life-threatening in healthy adults, unlike alcohol or benzodiazepine withdrawal, which can cause fatal seizures. The primary medical risks are dehydration and aspiration from severe vomiting.

Guidelines from organizations like the American Society of Addiction Medicine and the World Health Organization describe a predictable withdrawal pattern often summarized as “wet and wired.” The body becomes “wet” from excess secretions and “wired” from autonomic overactivation. Early symptoms usually begin 6 to 12 hours after short-acting opioids or around 30 hours after methadone. These symptoms include tearing, runny nose, sweating, yawning, anxiety, irritability, and intense drug cravings. Symptoms typically peak around 72 hours and include nausea, vomiting, diarrhea, abdominal cramping, muscle aches, bone pain, restlessness, dilated pupils, tremors, tachycardia, hypertension, and gooseflesh — or piloerection — which is where the term “cold turkey” originates.

Withdrawal severity is commonly measured using the Clinical Opiate Withdrawal Scale, or COWS. This scale evaluates heart rate, sweating, pupil size, GI upset, tremor, restlessness, anxiety, bone or joint aches, and runny nose or tearing. A critical clinical rule is that buprenorphine should generally not be started until a patient reaches mild to moderate withdrawal, typically a COWS score of 8 to 12 or higher. Starting buprenorphine too early can trigger precipitated withdrawal because it strongly displaces other opioids from the receptor.

Medication-assisted withdrawal management is strongly recommended because it reduces symptom severity, improves comfort, helps retain patients in treatment, and lowers relapse risk. Abrupt unsupported opioid cessation is discouraged, and ultra-rapid opioid detoxification is not recommended due to serious safety risks.

The first pillar of treatment is opioid agonist therapy. Buprenorphine is a partial μ-opioid receptor agonist with a ceiling effect on respiratory depression, making it safer than full agonists in many situations. It is often combined with naloxone in formulations like Suboxone. Buprenorphine is typically started 12 to 18 hours after short-acting opioids or 24 to 48 hours after long-acting opioids like methadone. Initial dosing commonly ranges from 4 to 16 milligrams daily and is tapered depending on clinical needs. Buprenorphine reduces withdrawal symptoms, cravings, relapse, and overdose risk.

Methadone is a full opioid agonist used in supervised opioid treatment programs or inpatient settings. Initial withdrawal doses are typically around 10 to 30 milligrams and are often tapered over 6 to 10 days. Maintenance dosing commonly ranges from 60 to 120 milligrams daily with gradual titration. Methadone prevents withdrawal, reduces cravings, and improves treatment retention.

The second pillar of treatment involves alpha-2 adrenergic agonists, which target the norepinephrine surge responsible for many autonomic symptoms. Lofexidine was the first FDA-approved non-opioid medication specifically for opioid withdrawal. Clonidine is also widely used off-label. Typical dosing ranges from 0.1 to 0.3 milligrams every 6 to 8 hours, up to 1.2 milligrams daily. Clonidine helps reduce sweating, tachycardia, anxiety, and hypertension, although it can cause hypotension and does not replace opioid agonist therapy.

The third pillar involves symptomatic “comfort medications.” Withdrawal treatment often includes targeted medications for symptom relief. Loperamide is commonly used for diarrhea, ondansetron for nausea, and dicyclomine for abdominal cramping. Pain and muscle symptoms are often treated with NSAIDs like ibuprofen, acetaminophen, or methocarbamol. Anxiety and insomnia may be treated with medications such as hydroxyzine or trazodone.

Withdrawal management alone is not definitive treatment for opioid use disorder. The goal is not simply to survive withdrawal, but to stabilize the nervous system, reduce suffering, prevent relapse, and transition patients into long-term treatment and recovery support. Medications like methadone and buprenorphine not only relieve withdrawal — they improve treatment retention, reduce relapse, lower overdose risk, and save lives.

Thanks for listening to AudioBoards. Stay tuned for more educational content in our next episode! The views and opinions expressed on the AudioBoards Podcast do not necessarily reflect those of our employers. This podcast is for educational purposes only and should not be used to diagnose or treat any medical conditions. It is not a substitute for professional medical advice. Always consult a qualified, board-certified healthcare provider for any medical concern.